DiGiovanna, Michael P - Yale University - Biological & Biomedical Sciences

个人简介

Dr. DiGiovanna is a native of Long Island, NY, who graduated from Cornell University in 1984 with a B.A. and a double major in the fields of biochemistry and music. He attended Yale University from 1984 through 1990 where he was earned the MD and PhD degrees, with his PhD in Pharmacology. He continued his post-graduate training at Yale, performing internship and residency in Internal Medicine, a research post-doctoral fellowship, and a clinical fellowship in Medical Oncology. He is currently an attending physician in Medical Oncology and Associate Professor of Medicine (Oncology) and Pharmacology at Yale University. His clinical specialty is breast cancer and he conducts both clinical and laboratory-based research. His translational laboratory research is focused on signal transduction in breast cancer. He also has a leadership role in education at the Yale School of Medicine, including current roles as Director of Pharmacology Curriculum and Director of Modules (clinical pathophysiology courses). PhD Yale University (1990) MD Yale University (1990) Fellow Yale University School of Medicine Postdoctoral Fellow Yale University Resident Yale University School of Medicine Board Certification AB of Internal Medicine, Medical Oncology (1997, recertified: 2007)

研究领域

Breast Neoplasms; Medical Oncology; Pharmacology; Protein-Tyrosine Kinases; Signal Transduction; Clinical Trial

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Koay, D.C, Zerillo, C., Narayan, M., Harris, L.N. and DiGiovanna, M.P., “Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations”, Breast Cancer Research, 12:R62 [Epub ahead of print], 2010 Chakraborty, A.K., Welsh, A., and DiGiovanna, M.P., “Co-Targeting IGF1R enhances growth-inhibitory and pro-apoptotic effects of antiestrogens in human breast cancer cell lines”, Breast Cancer Research and Treatment, DOI: 10.1007/s10549-009-0382-5 (2009), 120:327, 2010 Chakraborty, A.K. Liang, K. and DiGiovanna, M.P., “Co-Targeting insulin-like growth factor I receptor and HER2: Dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer”, Cancer Research, 68:1538-1545, 2008 Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. DiGiovanna, M.P., Stern, D.F., Edgerton, S., Broadwater, G., Dressler, L., Budman, D.R., Henderson, I.C., Norton, L., Liu, E.T., Muss, H.B., Berry, D., Hayes, D.F. and Thor, A.D., (2008) Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. DiGiovanna, M.P., Stern, D.F., Edgerton, S., Whalen, S.G., Moore, D. and Thor, A.D. (2005). ErbB-2 activation, epidermal growth factor receptor expression and prognosis in breast cancer patients. J. Clin. Oncology 23:1152-1160. Wang, C.-X., Koay, D.C., Edwards, A., Lu, Z., Mor, G., Ocal, I.T., and DiGiovanna, M.P., “In vitro and in vivo effects of combination of trastuzumab (Herceptin) and tamoxifen in breast cancer”, Breast Cancer Research and Treatment, 92:251-263, 2005 Argiris, A., Wang, C.-X., Whalen, S.G., and DiGiovanna, M.P. (2004). Synergistic interactions between tamoxifen and Trastuzumab (Herceptin). Clinical Cancer Res. 10:1409-1420. Chakraborty A, Hatzis C, DiGiovanna MP: Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease. Breast Cancer Res Treat. 2017 May; 2017 Feb 24. PMID: 28236033 Yushak ML, Han G, Bouberhan S, Epstein L, DiGiovanna MP, Mougalian SS, Sanft TB, Abu-Khalaf MM, Chung GG, Stein SM, Goldberg SB, Pusztai L, Hofstatter EW: Patient preferences regarding incidental genomic findings discovered during tumor profiling. Cancer. 2016 May 15; 2016 Mar 11. PMID: 26970385 Chakraborty AK, Zerillo C, DiGiovanna MP: In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib. Breast Cancer Res Treat. 2015 Aug; 2015 Jul 21. PMID: 26195122 Mougalian SS, Soulos PR, Killelea BK, Lannin DR, Abu-Khalaf MM, DiGiovanna MP, Sanft TB, Pusztai L, Gross CP, Chagpar AB: Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer. 2015 Aug 1; 2015 Apr 22. PMID: 25902916 Abu-Khalaf MM, Baumgart MA, Gettinger SN, Doddamane I, Tuck DP, Hou S, Chen N, Sullivan C, Lezon-Geyda K, Zelterman D, Hatzis C, Deshpande H, Digiovanna MP, Azodi M, Schwartz PE, Harris LN: Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors. Cancer. 2015 Jun 1; 2015 Feb 3. PMID: 25649370 Chakraborty AK, Mehra R, Digiovanna MP: Co-targeting ER and HER family receptors induces apoptosis in HER2-normal or overexpressing breast cancer models. Anticancer Res. 2015 Mar. PMID: 25750271 Acevedo-Gadea C, Hatzis C, Chung G, Fishbach N, Lezon-Geyda K, Zelterman D, DiGiovanna MP, Harris L, Abu-Khalaf MM: Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy. Breast Cancer Res Treat. 2015 Feb; 2015 Feb 17. PMID: 25687356 Fenn KM, Evans SB, McCorkle R, DiGiovanna MP, Pusztai L, Sanft T, Hofstatter EW, Killelea BK, Knobf MT, Lannin DR, Abu-Khalaf M, Horowitz NR, Chagpar AB: Impact of financial burden of cancer on survivors' quality of life. J Oncol Pract. 2014 Sep; 2014 May 27. PMID: 24865220 Brown JR, DiGiovanna MP, Killelea B, Lannin DR, Rimm DL: Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer. Lab Invest. 2014 Jan; 2013 Nov 4. PMID: 24189270 Schulman-Green D, Bradley EH, Knobf MT, Prigerson H, DiGiovanna MP, McCorkle R: Self-management and transitions in women with advanced breast cancer. J Pain Symptom Manage. 2011 Oct; 2011 Mar 27. PMID: 21444183 Chakraborty AK, Welsh A, Digiovanna MP: Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines. Breast Cancer Res Treat. 2010 Apr; 2009 Apr 1. PMID: 19337828 Koay DC, Zerillo C, Narayan M, Harris LN, DiGiovanna MP: Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations. Breast Cancer Res. 2010; 2010 Aug 9. PMID: 20696059 Christy CJ, Thorsteinsson D, Grube BJ, Black D, Abu-Khalaf M, Chung GG, DiGiovanna MP, Miller K, Higgins SA, Weidhaas J, Harris L, Tavassoli FA, Lannin DR: Preoperative chemotherapy decreases the need for re-excision of breast cancers between 2 and 4 cm diameter. Ann Surg Oncol. 2009 Mar; 2009 Jan 9. PMID: 19132447 Nishihori T, Choi J, DiGiovanna MP, Thomson JG, Kohler PC, McGurn J, Chung GG: Carpal tunnel syndrome associated with the use of aromatase inhibitors in breast cancer. Clin Breast Cancer. 2008 Aug. PMID: 18757265 Grube BJ, Christy CJ, Black D, Martel M, Harris L, Weidhaas J, Digiovanna MP, Chung G, Abu-Khalaf MM, Miller KD, Higgins SA, Philpotts L, Tavassoli FA, Lannin DR: Breast sentinel lymph node dissection before preoperative chemotherapy. Arch Surg. 2008 Jul. PMID: 18645113 DiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson IC, Norton L, Liu ET, Muss HB, Berry DA, Hayes DF, Thor AD: Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. J Clin Oncol. 2008 May 10; 2008 Apr 7. PMID: 18390970 Chakraborty AK, Liang K, DiGiovanna MP: Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer. Cancer Res. 2008 Mar 1. PMID: 18316619